These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 23597455)

  • 1. [Prognostic analysis of non-cytogenetic factors in elderly adults with acute myeloid leukemia].
    Zhao BB; Zhu Z; Xu PP; Li JM; Shen ZX; Zhao WL; Wang L
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jan; 34(1):3-7. PubMed ID: 23597455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of remission induction chemotherapy and prognostic analysis in elderly patients with acute myeloid leukemia].
    Zheng ZH; Hu JD; Liu TB; Chen XJ; Li J; Chen BY; Zheng XY
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):79-83. PubMed ID: 22730652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
    J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
    Colovic M; Colovic N; Radojkovic M; Stanisavljevic D; Kraguljac N; Jankovic G; Tomin D; Suvajdzic N; Vidovic A; Atkinson HD
    Ann Hematol; 2012 Sep; 91(9):1363-70. PubMed ID: 22592651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study of prognostic related factors of elderly patients with T/NK cell lymphoma].
    Wang Y; Qian Y; Wu LL; Zhao BB; Xu PP; Zhao WL; Wang L
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jan; 34(1):12-5. PubMed ID: 23597457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.
    Pigneux A; Harousseau JL; Witz F; Sauvezie M; Bene MC; Luquet I; Hunault-Berger M; Recher C; Lioure B; Himberlin C; Escoffre-Barbe M; Berthou C; Lissandre S; Fegueux N; Cahn JY; Jourdan E; Dreyfus F; Reiffers J; Milpied N; Ifrah N
    J Clin Oncol; 2010 Jun; 28(18):3028-34. PubMed ID: 20479424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
    Shao B; Gao YR; Wang C; Yan SK; Cai Q; Jiang JL; Yang J; Bai HT; Zhao M; Zhao CX
    Ai Zheng; 2006 Aug; 25(8):1007-12. PubMed ID: 16965684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
    Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.
    Gardin C; Chevret S; Pautas C; Turlure P; Raffoux E; Thomas X; Quesnel B; de Revel T; de Botton S; Gachard N; Renneville A; Boissel N; Preudhomme C; Terré C; Fenaux P; Bordessoule D; Celli-Lebras K; Castaigne S; Dombret H
    J Clin Oncol; 2013 Jan; 31(3):321-7. PubMed ID: 23248249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study.
    Behringer B; Pitako JA; Kunzmann R; Schmoor C; Behringer D; Mertelsmann R; Lübbert M
    Ann Hematol; 2003 Jul; 82(7):381-9. PubMed ID: 12756497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
    Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of efficacy and prognosis of induction chemotherapy in 76 elderly patients with acute myeloid leukemia (non-APL)].
    Yang H; Niu JH; Zhu CY; Zhang Q; Zhu HY; Yao ZL; Zhou MH; Wang QS; Yu L; Jing Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):957-64. PubMed ID: 25130810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
    Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
    Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preliminary study of HCT-CI score system for prognosis prediction in elderly patients with acute myeloid leukemia after chemotherapy].
    Shi J; Zhang Y; Ma BG; Sun K; Lei PC; Zhu ZM; Zang YZ; Chen YQ; Guo JM; Yang J; Liu ZW
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jan; 34(1):8-11. PubMed ID: 23597456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of prognostic variables in childhood acute myeloid leukemia].
    Gu LJ; Tie LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Ye H; Wang YP; Dong L
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):10-3. PubMed ID: 16732931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
    Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
    Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors.
    Stasi R; Venditti A; Del Poeta G; Aronica G; Dentamaro T; Cecconi M; Stipa E; Scimò MT; Masi M; Amadori S
    Cancer; 1996 Jun; 77(12):2476-88. PubMed ID: 8640696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
    Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
    Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study.
    Kornblau SM; Andreeff M; Hu SX; Xu HJ; Patel S; Theriault A; Koller C; Kantarjian H; Estey E; Deisseroth AB; Benedict WF
    Clin Cancer Res; 1998 Aug; 4(8):1955-63. PubMed ID: 9717825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.